Los Angeles Capital Management’s Cytokinetics CYTK Stock Holding History

Los Angeles Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$95.1K	Sell	1,116 -15	-1%	-$1.08K	﹤0.01%	1356
2026 Q1	$74.5K	Sell	1,131 -5,040	-82%	-$320K	﹤0.01%	1409
2025 Q4	$384K	Buy	+6,171	New	+$384K	﹤0.01%	1001
2024 Q4	–	Sell	-5,219	Closed	-$276K	–	1143
2024 Q3	$276K	Sell	5,219 -9,408	-64%	-$524K	﹤0.01%	1037
2024 Q2	$792K	Sell	14,627 -3,190	-18%	-$193K	﹤0.01%	731
2024 Q1	$1.25M	Buy	+17,817	New	+$1.38M	﹤0.01%	619
2018 Q3	–	Sell	-11,059	Closed	-$92K	–	1409
2018 Q2	$92K	Hold	11,059	–	–	﹤0.01%	1418
2018 Q1	$80K	Sell	11,059 -15,689	-59%	-$135K	﹤0.01%	1301
2017 Q4	$218K	Sell	26,748 -28,339	-51%	-$322K	﹤0.01%	1251
2017 Q3	$799K	Buy	+55,087	New	+$752K	﹤0.01%	890
2016 Q1	–	Sell	-12,470	Closed	-$130K	–	1146
2015 Q4	$130K	Buy	+12,470	New	+$122K	﹤0.01%	1097

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Los Angeles Capital Management's CYTK Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Cytokinetics (CYTK) stake by 1.3% in Q2 2026, selling an estimated $1.08K and leaving 1,116 shares worth $95.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1356.

Los Angeles Capital Management first reported a position in CYTK in Q4 2015 and has held it in 11 quarters since. The position peaked at $1.25M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Los Angeles Capital Management held 1,116 shares of Cytokinetics worth $95.1K as of Q2 2026.
Los Angeles Capital Management sold 15 Cytokinetics shares in Q2 2026, an estimated $1.08K.
Cytokinetics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1356 holding.
Los Angeles Capital Management first reported a position in Cytokinetics in Q4 2015 and has held it in 11 quarters since.
Los Angeles Capital Management's Cytokinetics position peaked at $1.25M in Q1 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.